HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer

2026-02-13 - 06:59

First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer TAIPEI, SHANGHAI and SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ — HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to HCB101